Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: A meta-analysis of randomized controlled trials.
Ying-Ying ZhangMin ZhangJia-Qi ZhangQiu-Qi LiMei-Ping LuLei ChengPublished in: International forum of allergy & rhinology (2023)
Omalizumab + AIT can significantly enhance the efficacy and safety of AIT by increasing TMD and SU to allergens, while decreasing severe systemic AEs.